Neurite outgrowth Influx constant Cancer immunotherapy Claudin Anti-GFAP encephalomyelitis Estradiol Glia Neurological immune-related adverse events MOG Jaundice Autoimmune diseases Blood–brain barrier Cannabinoid receptor type 2 Children Circadian clock Myelin oligodendrocyte glycoprotein Astrocyte Microenvironment Microglia Encephalitis GABA Cannabinoid receptor type 2 Endocannabinoid system Microglia Neuroinflammation Drosophila MOG-IgG associated disorders MOGAD Animal model Area postrema syndrome Cerebrospinal fluid Reproductive assistance Breastfeeding Central nervous system Autoimmune encephalitis Gunn MRI Optic neuritis Immunosuppressant Blood-brain barrier Multiple sclerosis MS Ependymal cell Hippocampus Lateral diffusion Aquaporin-4 antibodies Blood-brain barriers Clinically isolated syndrome CIS Connexins Adult neurogenesis Autoantibodies Adverse events Bone B cells Toll-like receptor Aquaporin-4 Relapses Myelitis Post-partum Immune checkpoint inhibitors LAT1 Collapsing response mediator protein CD14 Endocannabinoid system Rituximab Pregnancy MOGAD Blood brain barrier Database Aquaporin-4-IgG AQP4-IgG Demyelination Biobank Neuraxial analgesia Neuroinflammation Ependymal cell neuromyelitis optica aquaporin-4 cilia sub-ventricular zone Choroid plexus GSK-3β Multiple sclerosis Cytokines CP Molecular biology Treatment response MOG antibodies CP Neuroscience Meninges CRMP5 Longitudinally extensive transverse myelitis Disease-modifying treatments Cilia Neuromyelitis optica Aquaporin-4 antibody Prognosis NMOSD Blood–CSF barrier Disease modifying treatments Amino acid COVID-19 ERRα Biomarkers Innate immune system Embryo Cancer Glutamate Bright Neural antibodies Registry